Immunotherapy for lung cancer: new era, new thinking
10.3872/j.issn.1007-385x.2019.02.001
- VernacularTitle:肺癌免疫治疗: 新时代，新思考
- Author:
BAI Rilan
1
;
CUI Jiuwei
1
Author Information
1. Cancer Center, the First Hospital of Jilin University
- Publication Type:Journal Article
- Keywords:
lung cancer;
immunotherapy;
response evaluation;
adverse event;
biomarkers
- From:
Chinese Journal of Cancer Biotherapy
2019;26(2):137-145
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitors have been continuously researched and developed, and gradually expanded in clinical practice, rapidly changing the treatment mode of lung cancer. At present, a number of immunotherapeutic drugs are also actively developed in China and gradually applied to clinical research, indicating that China has entered a new era of immunotherapy. However, with the continuous expansion of clinical research and the continuous accumulation of experimental data, it also brings us many new challenges and new thinking. This article mainly analyzes the development status and challenges of immunotherapy for lung cancer in the aspects of breakthroughs in treatment modes, special populations excluded from clinical immunotherapy trials, response evaluation, treatment-related adverse events and predictive biomarkers.
- Full text:20190201.pdf
